This website is intended for healthcare professionals only

Trending Topic

Close-up of a person rubbing their temple, depicting persistent headache pain
13 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Migraines profoundly impact well-being, especially in children and adolescents. From 1990 to 2021, global pediatric migraine disability has increased, with particular vulnerability in females and adolescents aged 15–19.1 A 2023 meta-analysis found the prevalence of primary headache diagnosis in individuals aged 8–18 years to be 62%.2 The prevalence of a migraine diagnosis was 11%; 8% […]

Marwan Sabbagh: Approval of Aducanumab for Alzheimer’s Disease

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jul 12th 2021

It was a great pleasure to meet up with Marwan Sabbagh (Cleveland Clinic Lerner College of Medicine, Las Vegas, NV, USA), to discuss the recent approval of aducanumab for Alzheimer’s Disease. Aducanumab was granted accelerated approval on June 7 2021, by the U.S. Food and Drug Administration (FDA).

Questions:

  1. Could you give us a brief overview of the clinical trial program that has led to the approval of aducanumab for Alzheimer’s disease? (0:09)
  2. Could you tell us more about the ongoing EMBARK study? (1:38)
  3. Why has aducanumab succeeded when so many other drugs have failed late stage clinical trials? (2:07)
  4. What are the challenges and opportunities presented by this approval? (4:01)
  5. What questions remain unanswered and what future studies are planned? (5:30)

Disclosures: Marwan Sabbagh receives research support from the NIH and the Keep Memory Alive Foundation; consulting agreements with Alzheon, Biogen, Cortexyme, Danone, Neurotrope, Regenron, Stage 2 Innovations, Acadia, and Roche-Genentech; stock options in Brain Health Inc., NeuroReserve, NeuroTau, Optimal Cognitive Health Co., uMethod Health,Versanum Inc. and Athira.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup